Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Eloralintide

NCT06230523

Eli Lilly · Phase 2 · Completed · Enrollment 263

NCT06230523

Y axis: Change in body weight from baseline, %

0-5-10-15-20048121620243648Placebo, week 48, -0.4%1 mg Eloralintide, week 48, -9%3 mg Eloralintide, week 48, -12%6 mg Eloralintide, week 48, -18%9 mg Eloralintide, week 48, -20%

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

  • Placebo, one timepoint
  • 1 mg Eloralintide, one timepoint
  • 3 mg Eloralintide, one timepoint
  • 6 mg Eloralintide, one timepoint
  • 9 mg Eloralintide, one timepoint
  • Placebo: week 48 -0.4%
  • 1 mg Eloralintide: week 48 -9%
  • 3 mg Eloralintide: week 48 -12%
  • 6 mg Eloralintide: week 48 -18%
  • 9 mg Eloralintide: week 48 -20%

One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.